Literature DB >> 26598106

Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk.

Francis E Lotrich1, Barry Sears2, Robert K McNamara3.   

Abstract

Although potentially modifiable risk factors for interferon-alpha (IFN-α)-associated depression (IFN-MDD) have been identified, it is not currently known how they interact to confer risk. In the present study we prospectively investigated interactions among poor sleep quality, high-stress, pre-existing depressive symptoms, and polyunsaturated fatty acid status. Non-depressed hepatitis C patients (n=104) were followed prospectively during IFN-α therapy. IFN-MDD occurs in 20-40% of patients and was diagnosed using the Structured Clinical Interview of DSM-IV (SCID-IV), with incidence examined using Cox regression. Baseline Pittsburgh Sleep Quality Inventory (PSQI), Perceived Stress Scale (PSS), Beck Depression Inventory (BDI), and a range of plasma long-chain fatty acid levels were measured (gas chromatography) - focusing on the ratio of arachidonic acid (AA) to docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (AA/EPA+DHA). The AA/EPA+DHA ratio (Β=0.40 ± 0.16; p=0.006), PSQI (Β=0.12 ± 0.04; p=0.001), PSS (Β=0.07 ± 0.02; p<0.001), and baseline BDI (Β=0.05 ± 0.02; p<0.001) each individually predicted IFN-MDD incidence. In step-wise Cox regression eliminating non-significant variables, two interactions remained significantly predictive: PSQI*AA/EPA+DHA (p=0.008) and PSS*AA/EPA+DHA (p=0.01). Receiver Operator Curves (ROC) were used to examine the specificity and sensitivity of IFN-MDD prediction. When sleep was normal (PSQI<5), AA/EPA+DHA was strongly predictive of IFN-MDD (AUC=91 ± 6; p=0.002). For example, among those with AA/EPA+DHA less than the median (4.15), none with PSQI<5 developed depression. Conversely, neither PSS nor PSQI was statistically associated with depression risk in those with an elevated AA/EPA+DHA ratio. These data demonstrate that the AA/EPA+DHA ratio moderates the effect of poor sleep on risk for developing IFN-MDD and may have broader implications for predicting and preventing MDD associated with inflammation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Arachidonic acid; Docosahexaenoic acid; Eicosapentaenoic acid; Interferon-alpha; Polyunsaturated fatty acids; Sleep quality

Mesh:

Substances:

Year:  2015        PMID: 26598106      PMCID: PMC4775327          DOI: 10.1016/j.plefa.2015.10.004

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  92 in total

1.  Causal relationship between stressful life events and the onset of major depression.

Authors:  K S Kendler; L M Karkowski; C A Prescott
Journal:  Am J Psychiatry       Date:  1999-06       Impact factor: 18.112

2.  Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

Authors:  L Capuron; A Ravaud
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

Review 3.  Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions.

Authors:  J M Mullington; D Hinze-Selch; T Pollmächer
Journal:  Ann N Y Acad Sci       Date:  2001-03       Impact factor: 5.691

4.  Paroxetine for the prevention of depression induced by high-dose interferon alfa.

Authors:  D L Musselman; D H Lawson; J F Gumnick; A K Manatunga; S Penna; R S Goodkin; K Greiner; C B Nemeroff; A H Miller
Journal:  N Engl J Med       Date:  2001-03-29       Impact factor: 91.245

5.  Inflammatory cytokines, socioeconomic status, and acute stress responsivity.

Authors:  Andrew Steptoe; Natalie Owen; Sabine Kunz-Ebrecht; Vidya Mohamed-Ali
Journal:  Brain Behav Immun       Date:  2002-12       Impact factor: 7.217

Review 6.  Cytokines, stress, and depressive illness.

Authors:  H Anisman; Z Merali
Journal:  Brain Behav Immun       Date:  2002-10       Impact factor: 7.217

7.  Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

Authors:  Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2002-05       Impact factor: 7.853

8.  Cognitive styles and life events interact to predict bipolar and unipolar symptomatology.

Authors:  N A Reilly-Harrington; L B Alloy; D M Fresco; W G Whitehouse
Journal:  J Abnorm Psychol       Date:  1999-11

9.  Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.

Authors:  Boris Nemets; Ziva Stahl; R H Belmaker
Journal:  Am J Psychiatry       Date:  2002-03       Impact factor: 18.112

10.  Higher maternal plasma docosahexaenoic acid during pregnancy is associated with more mature neonatal sleep-state patterning.

Authors:  Sunita R Cheruku; Hawley E Montgomery-Downs; Susanna L Farkas; Evelyn B Thoman; Carol J Lammi-Keefe
Journal:  Am J Clin Nutr       Date:  2002-09       Impact factor: 7.045

View more
  3 in total

Review 1.  Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.

Authors:  Erik Messamore; Daniel M Almeida; Ronald J Jandacek; Robert K McNamara
Journal:  Prog Lipid Res       Date:  2017-01-06       Impact factor: 16.195

Review 2.  Potential Psychoactive Effects of Microalgal Bioactive Compounds for the Case of Sleep and Mood Regulation: Opportunities and Challenges.

Authors:  Bozena McCarthy; Graham O'Neill; Nissreen Abu-Ghannam
Journal:  Mar Drugs       Date:  2022-07-29       Impact factor: 6.085

3.  Omega-3 long-chain polyunsaturated fatty acid and sleep: a systematic review and meta-analysis of randomized controlled trials and longitudinal studies.

Authors:  Ying Dai; Jianghong Liu
Journal:  Nutr Rev       Date:  2021-07-07       Impact factor: 7.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.